New era of epidermal growth factor receptor-tyrosine kinase inhibitors for lung cancer

Table 1 Results from studies with tyrosine kinase inhibitor’s in 1^st line treatment of non-small cell lung cancer

Study and ref.	n	Treatment	RR (%)	P	PFS (mo)	HR	OS (mo)	HR
						P		P
IPASS[9]	437	Gefitinib/	71.2/47.3	0.01	9.5/5.3	0.48	21.6/21.9	0.99
		Carboplatin + Paclitaxel				(< 0.001)
WJTOG[10]	177	Gefitinib/	62.1/32.2	0.01	9.2/6.3	0.49	30.9/NA	1.64
		Cisplatin + Docetaxel				-0.001
NEJ[11]	230	Gefitinib/	73.7/30.7	0.01	10.8/5.4	0.3	30.5/23.6	NA
		Carboplatin + Paclitaxel				-0.001
OPTIMAL[12]	154	Erlotinib/	83/36	0.01	13.1/4.6	0.16	22.6/28.8	1.06
		Carboplatin + Gemcitabin				-0.001
EURTAC[13]	173	Erlotinib/	58/15	0.01	9.7/5.2	0.37	19.3/19.5	1.04
		Platin doublet				-0.001
LUX-LUNG3[14]	345	Afatinib/	56/23	0.01	11.1/6.9	0.58	NA	1.12
		Cisplatin + pemetrexed				-0.001

NA: Not available; RR: Response rate; PFS: Progression free survival; HR: Hazard ratio; OS: Overall survival.